Axogen Inc vs Lowe`s Companies Inc — how do they compare? Axogen Inc trades at $48.35 (market cap $2.59B), while Lowe`s Companies Inc trades at $220.63 (market cap $122.73B). The key difference: Lowe`s Companies Inc is far larger — about 47.4× Axogen Inc's market cap, and Lowe`s Companies Inc pays a 2.28% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | LOW | |
|---|---|---|
Market Cap | $2.59B | $122.73B |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $287.39 |
52-Week Low | $14.16 | $201.92 |
Enterprise Value | $2.50B | $164.48B |
Dividend Yield | — | 2.28% |
Signals from Pluang's Aura AI — not financial advice
AXGN is trading at $46.43, up 4.69% today, with strong technical momentum and bullish moving average signals. The company reported Q2 2026 revenue growth of 23.1% to $69.7 million and raised full-year guidance to at least $279 million. Despite recent earnings misses, analyst sentiment remains overwhelmingly positive with 84% buy ratings and a $54.33 price target.
The stock presents growth potential driven by expanding nerve care platform adoption and reimbursement improvements, but faces risks from persistent net losses (-$15.7M in 2025) and high valuation multiples (P/S 9.5). Near-term performance hinges on Q3 earnings delivery and continued commercial execution amid competitive pressures.
Lowe's (LOW) trades at $223.35, up 2.24% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $257.69. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Fundamentals show solid profitability with a net income margin of 7.51% and a P/E ratio of 18.88, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights mixed sentiment, with some institutional selling but optimism around the Pro business segment.
The outlook for LOW is cautiously optimistic, supported by strong analyst buy ratings (60.79%) and a dividend payout. Key risks include competitive pressures, macroeconomic sensitivity, and high debt levels. The upcoming Q2 earnings report on August 19, 2026, will be critical for validating growth expectations and could drive near-term price movement.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →